The serum levels of CRP, IL-6, IL-10 and TNF- in the patients of the two groups after treatment were increased compared with those before treatment (P<0.05). amputation. The therapeutic effects of patients in the two groups were compared. The levels of serum C-reactive protein (CRP), interleukin-6 (IL-6), IL-10 and tumor necrosis factor- (TNF-) of patients in the two groups were measured by enzyme-linked immunosorbent assay (ELISA) before treatment and at one week after treatment. The levels of immunoglobulin G (IgG), IgA and IgM were detected by immunoturbidimetry. The quality of life (QOL) in patients was evaluated by quality-of-life index (iQOL) before and after treatment. The total effective rate in the observation group was significantly higher than that in the control group (P<0.05). The serum levels of CRP, IL-6, IL-10 and TNF- of patients in the two groups were higher at one week after treatment than those before treatment (P<0.05), and there were no significant differences between the two groups (P>0.05). At one week after treatment, IgG, IgM and IgA levels of patients in the two groups were remarkably increased (P<0.05), and there were no significant differences between the two groups (P>0.05). After treatment, the iQQL scores of patients in the two groups were significantly decreased, and iQQL score in observation group was decreased more significantly compared with that in control group (P<0.05). Compared with drug therapy, minimally invasive surgery is more effective in the treatment of palmar and foot hyperhidrosis with smaller trauma and inflammatory reaction, and it has less influence on serum immunoglobulin levels, which is conducive to the rehabilitation of patients. Keywords: hyperhidrosis, minimally invasive surgery, serum cytokines, immunoglobulins Introduction Palmar and foot hyperhidrosis is a common disease caused by excessive activation of the sympathetic nervous system leading to autonomic excessive secretion of head and facial sweat glands thus resulting in the increased sweating (1). The incidence rate of palmar and foot hyperhidrosis is approximately 1.0% in the Western countries. The epidemiological investigation in China displays that the incidence rate is approximately 4.6% in college and secondary school students in Fuzhou. The corresponding symptoms generally can be found during the elementary school period among patients with palmar and foot hyperhidrosis. Although the disease cannot affect the health and longevity of patients, it causes inconvenience to their work, study and social life, and have a greater impact on their quality of life (2,3). The therapies of palmar and foot hyperhidrosis include internal medicine and surgery. The effect of drug therapy is poor, with greater side effects, and the long-term use is easy to produce immune tolerance, and relapse easily occurs once the drug is discontinued (4). In the 1980s, the clinical application of thoracoscope contributed to the rapid development of the minimally invasive surgery of palmar and foot hyperhidrosis. It has the advantages of small trauma, quick recovery and remarkable curative effect (5). Minimally invasive surgery was Fosbretabulin disodium (CA4P) conducted in patients with palmar and foot hyperhidrosis in this study and obtained satisfactory curative effect. Materials and methods General information Seventy-six patients with palmar and foot hyperhidrosis admitted to Yunnan University Fosbretabulin disodium (CA4P) Hospital from August 2014 to July 2016 were selected and randomly divided into control group (n=38) and observation group Fosbretabulin disodium (CA4P) (n=38) using the random number table. Inclusion criteria: i) Patients met the diagnostic criteria of primary hyperhidrosis; ii) patients with main clinical symptoms of much palmar and foot sweating, lasting more than six months, over more than once every week; iii) patients with hyperhidrosis affecting daily activities; and iv) patients signed the inform consent. Exclusion criteria: i) Patients with severe heart, brain, liver or psychiatric disorders; and ii) patients with severe coagulation disorders and drug allergy to the drug. The differences in general data of patients in two groups were not statistically significant (P>0.05) (Table I). The study was approved by the Ethics Committee of Sun Yat-Sen University (Guangdong, China). Table I. General data of objects of study.
Sex (male/female)24/1426/120.2340.629Age (year old)18C4018C45Average age (year old)25.365.6325.855.730.3760.708Duration of illness (year)11.622.4611.252.370.6680.506BMI (kg/m2)23.433.2722.873.580.7120.479Severe degree (n, %)??Mild??4 (10.52)3 (7.89)0.0010.999??Moderate16 (42.11)19 (50.00)0.2110.645??Severe18 (47.37)16 (42.11)0.0530.818 Open in a separate window Drug therapy Drug therapy was used in the control group. Before treatment, patients underwent a general physical examination. Patients with Fosbretabulin disodium (CA4P) a history of drug allergy were excluded, and the range of Fosbretabulin disodium (CA4P) sweating was measured by the iodine-starch check. Twenty shot sites had been designed at each aspect from the hands and foot (1.0 cm apart). Botulinum toxin type A (100 systems) was diluted using 3 ml sodium chloride Chuk alternative, and subcutaneous shot was conducted based on the designed shot sites (the quantity of shot at each shot site was around 2.5 systems). Interest was paid that.